Evidence map›Paper›PMID 29659727›Full record

ArticleCardiovascular research2018

Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation.

Alessandra Borgognone, Eduard Shantsila, Sophie M Worrall, Eakkapote Prompunt, Thomas Loka, Brodie L Loudon, Myriam Chimen, G Ed Rainger, Janet M Lord, Ashley Turner and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Immunohistochemical characteristics of coronary thrombi in ST-elevation myocardial infarction.American heart journal plus : cardiology research and practice · 2022
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Alessandra BorgognoneInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Eduard ShantsilaInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Sophie M WorrallInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Eakkapote PrompuntInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Thomas LokaInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Brodie L LoudonNorwich Medical School, University of East Anglia, Norwich NR4 7UQ, UK.
Myriam ChimenInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
G Ed RaingerInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Janet M LordInstitute of Inflammation and Ageing, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Ashley TurnerSandwell and West Birmingham NHS Trust, City Hospital, Birmingham B18 7QH, UK.
Peter NightingaleWellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TT, UK.
Martin FeelischClinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Gregory Y H LipInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Steve P WatsonInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Michael P FrenneauxNorwich Medical School, University of East Anglia, Norwich NR4 7UQ, UK.
Melanie MadhaniInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
University of Birmingham · GBUniversity of East Anglia · GBQueen Elizabeth Hospital · GBUniversity of Southampton · GB

Funding

Department of HealthMedical Research Council G1001536
6 · The paper itself

Abstract

Aims: Heart failure (HF) is a pro-thrombotic state. Both platelet and vascular responses to nitric oxide (NO) donors are impaired in HF patients with reduced ejection fraction (HFrEF) compared with healthy volunteers (HVs) due to scavenging of NO, and possibly also reduced activity of the principal NO sensor, soluble guanylate cyclase (sGC), limiting the therapeutic potential of NO donors as anti-aggregatory agents. Previous studies have shown that nitrite inhibits platelet activation presumptively after its reduction to NO, but the mechanism(s) involved remain poorly characterized. Our aim was to compare the effects of nitrite on platelet function in HV vs. HF patients with preserved ejection fraction (HFpEF) and chronic atrial fibrillation (HFpEF-AF), vs. patients with chronic AF without HF, and to assess whether these effects occur independent of the interaction with other formed elements of blood. Methods and results: Platelet responses to nitrite and the NO donor sodium nitroprusside (SNP) were compared in age-matched HV controls (n = 12), HFpEF-AF patients (n = 29), and chronic AF patients (n = 8). Anti-aggregatory effects of nitrite in the presence of NO scavengers/sGC inhibitor were determined and vasodilator-stimulated phosphoprotein (VASP) phosphorylation was assessed using western blotting. In HV and chronic AF, both nitrite and SNP inhibited platelet aggregation in a concentration-dependent manner. Inhibition of platelet aggregation by the NO donor SNP was impaired in HFpEF-AF patients compared with healthy and chronic AF individuals, but there was no impairment of the anti-aggregatory effects of nitrite. Nitrite circumvented platelet NO resistance independently of other blood cells by directly activating sGC and phosphorylating VASP. Conclusion: We here show for the first time that HFpEF-AF (but not chronic AF without HF) is associated with marked impairment of platelet NO responses due to sGC dysfunction and nitrite circumvents the 'platelet NO resistance' phenomenon in human HFpEF, at least partly, by acting as a direct sGC activator independent of NO.

Indexed as

Stroke VolumeVentricular Function, LeftAgedAged, 80 and overAtrial FibrillationBlood PlateletsCase-Control StudiesCell Adhesion MoleculesChronic DiseaseDrug ResistanceFemaleHeart FailureHumansMaleMicrofilament ProteinsNitric OxideCell Adhesion MoleculesMicrofilament ProteinsNitric OxideNitric Oxide DonorsNitroprussidePhosphoproteinsSodium NitriteSoluble Guanylyl CyclaseVasodilator-Stimulated Phosphoprotein

Identifiers

PMID29659727
PMCPMC6054254
OpenAlexW2797769189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.